Corrigendum to: Leukemia advance online publication, 6 September 2007; doi:10.1038/sj.leu.2404934

Since the publication of the above letter online, the authors have noticed a couple of errors in the identification of high-risk patients affecting the survival comparison.

First, the 70-gene, rather than the 17-gene, molecular signature was applied to the Mayo data set, using the expression of only probe sets that have been represented on the U133A Affyemtrix chip. The survival of the high-risk patients (n=10) was only 12.5 months compared to 55.1 months for the other patients (log-rank P=0.0009).

Second, there was also an error in calculating the 17-gene index for the UAMS cohort. Using the correct formula (200638_s_at × 0.283)−(1557277_a_at × 0.296)−(200850_s_at × 0.208)+(201897_s_at × 0.314)−(202729_s_at × 0.287)+(203432_at × 0.251)+(204016_at × 0.193)+(205235_s_at × 0.269)+(206364_at × 0.375)+(206513_at × 0.158)+(211576_s_at × 0.316)+(213607_x_at × 0.232)−(213628_at × 0.251)−(218924_s_at × 0.23)−(219918_s_at × 0.402)+(220789_s_at × 0.191)+(242488_at × 0.148)−10.28, high-risk patients with t(4;14) (n=8) have significantly shorter survival than high-risk patients without t(4;14) (n=33), median overall survival of 11.6 months vs 27.3 months, log-rank P=0.005.

In essence, the conclusions drawn from the original letter remain the same. We apologize for any inconvenience caused.